«Farmak» 3R’s: Reduce, Reuse, Recycle
Period of implementation of the project:
Started in 2018, since now
Hundreds of thousands of tons of polyethylene waste are generated in Ukraine every year. Only a small part of the total is processed. To change the picture, Farmak wants to show by example that it is necessary to sort and dispose waste for recycling in order to avoid environmental pollution by polyethylene waste, to reduce man-made pressure on the environment, polygons and landfills.
Our world is flooded with plastic waste. What at first seemed practical, hygienic and cheap has become a grand problem, the solution of which does not seem to exist. But some countries and companies show by their example that it is possible to reduce the amount of plastic waste by sending it for recycling. This trend is growing. Farmak, is a pharmaceutical company, whose production lines are certified according to GMP, cares not only about the quality and safety of products, but also about environmental protection. The company has more than 300 products in its portfolio – medicines, medical devices, dietary supplements. During the production of medicines in plastic bottles are formed waste polyethylene – scrap. In 2019, it amounted more than 250 tons, and in the first half of 2020 is already almost 90 tons. By increasing production, the Company seeks to minimize the impact on the environment. In addition to optimization measures to reduce the usage of polyethylene, Farmak gives all the scrap for recycling.
Under the project in 2019, the amount of transferred polyethylene waste from the production of medicines vials was about 250 tons, and in the first half of 2020 – almost 90 tons. That is all the received scrap that is transferred for processing. In the future, it can be used to make a variety of goods and components.
Company: Farmak JSC
About the company:
Farmak JSC is an Ukrainian manufacturer of medicines of European level. Since 2010 it is the leader of the pharmaceutical market of Ukraine. There are more than 220 product files in the company’s portfolio. Up to 20 new medicinal products are marketed annually.
The products are exported to 28 countries. The company has 19 production lines, 5 laboratories, R&D complex and API production. The company employs more than 2,700 people.